Program
baricitinib
Also written as “Baricitinib”, “LY3009104” and “INCB028050”.
Its studies are mostly in Arthritis, Rheumatoid · Dermatitis, Atopic · Lupus Erythematosus, Systemic · COVID-19 · Arthritis, Juvenile, led by 5 companies.
Drug pageBaricitinib: every studyMany companies study it; this page follows only the 58 they lead. All 149 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lillyits history only | 546 open or running | phase 4since Apr 12, 2019 | Aug 18, 2010 | Mar 2028phase 3 · NCT05723198 |
| Galvani Bioelectronicsits history only | 11 open or running | no phasesince Jul 5, 2021 | Jul 5, 2021 | Jul 2027NCT05003310 |
| Genuine Research Center, Egyptits history only | 10 open or running | phase 1since Aug 9, 2021 | Aug 9, 2021 | none ahead |
| Incepta Pharmaceuticalsits history only | 10 open or running | phase 3since Sep 20, 2021 | Sep 20, 2021 | none ahead |
| Incyteits history only | 10 open or running | phase 2since May 13, 2009 | May 13, 2009 | none ahead |
Also a collaborator on its studies: Q2 Solutions and Horus Pharma.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 42 studies since May 13, 2009.
- Feb 14, 2019Phase 3 study in Lupus Erythematosus, SystemicEli Lilly · NCT03843125 · 1,147 enrolled · United States, Argentina, Australia and more
- Apr 1, 2019Phase 3 study in Alopecia AreataEli Lilly · NCT03899259 · 606 enrolled · United States, Argentina, Australia and more
- Apr 12, 2019Phase 4 study in Arthritis, RheumatoidEli Lilly · NCT03915964 · 2,659 enrolled · United States, Australia, Austria and more
- May 15, 2019Phase 3 study in Dermatitis, AtopicEli Lilly · NCT03952559 · 516 enrolled · Argentina, Australia, Austria and more
- Sep 10, 2019Phase 4 study in Arthritis, RheumatoidEli Lilly · NCT04086745 · 1,050 enrolled · United States
- Sep 11, 20192 phase 3 studiesEli Lilly · NCT04088409, NCT04088396
- Jun 5, 2020Phase 3 study in COVID-19Eli Lilly · NCT04421027 · 1,525 enrolled · United States, Argentina, Brazil and more
- Aug 17, 2020Phase 3 study in Nakajo syndromeEli Lilly · NCT04517253 · 10 enrolled · Japan
- Jul 5, 2021Galvani Bioelectronics’ first study: no phase study in Arthritis, RheumatoidNew to Galvani BioelectronicsGalvani Bioelectronics · NCT05003310 · 28 planned · United States, Netherlands
- Aug 9, 2021Genuine Research Center, Egypt’s first study: phase 1 study in HealthyNew to Genuine Research Center, EgyptGenuine Research Center, Egypt · NCT05006768 · 30 enrolled · Egypt
- Sep 20, 2021Incepta Pharmaceuticals’ first study: phase 3 study in COVID-19New to Incepta PharmaceuticalsIncepta Pharmaceuticals · NCT05056558 · Bangladesh
- Oct 8, 2021Phase 3 study in COVID-19Eli Lilly · NCT05074420 · 6 enrolled · United States, Brazil, Mexico and more
- Feb 3, 2023Phase 3 study in AlopeciaEli Lilly · NCT05723198 · 595 planned · United States, Argentina, Australia and more
- Oct 27, 20252 phase 3 studies in Diabetes Mellitus, Type 1Eli Lilly · NCT07222332, NCT07222137
Ahead
- Jul 2027Primary completion: no phase study in Arthritis, RheumatoidGalvani Bioelectronics · NCT05003310
- Mar 2028Primary completion: phase 3 study in AlopeciaEli Lilly · NCT05723198
- Jul 2028Primary completion: phase 3 study in Diabetes Mellitus, Type 1Eli Lilly · NCT07222332
- Jul 2031Primary completion: phase 3 study in Diabetes Mellitus, Type 1Eli Lilly · NCT07222137
TargetBeta
“An orally bioavailable inhibitor of Janus kinases 1 and 2 (JAK1/2), ”NCIt, by rule
“Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ruxolitinibrule | Incyte | phase 4 | 95 |
| tofacitinibrule | Pfizer | phase 4 | 94 |
| upadacitinibrule | AbbVie | phase 4 | 64 |
| filgotinib maleaterule | Eisai | phase 4 | 2 |
| filgotinibrule | Lakefront Biotherapeutics NV | phase 3 | 46 |
| jaktinibrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 31 |
| delgocitinibrule | LEO Pharma | phase 3 | 21 |
| momelotinibrule | GlaxoSmithKline | phase 3 | 17 |
Studies
All 58 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07222332Diabetes Mellitus, Type 1 · United States, Australia, Belgium and more | 3 | Recruiting | Eli Lilly | Jul 2028 | 300 |
| NCT07222137Diabetes Mellitus, Type 1 · United States, Australia, Belgium and more | 3 | Recruiting | Eli Lilly | Jul 2031 | 150 |
| NCT05723198Alopecia · United States, Argentina, Australia and more | 3 | Recruiting | Eli Lilly | Mar 2028 | 595 |
| NCT05074420COVID-19 · United States, Brazil, Mexico and more | 3 | Terminated | Eli Lilly | Sep 5, 2024 | 6 |
| NCT05056558COVID-19 · Bangladesh | 3 | Withdrawn | Incepta Pharmaceuticals | Jul 30, 2025 | 0 |
| NCT05006768Healthy · Egypt | 1 | Completed | Genuine Research Center, Egypt | Jun 3, 2021 | 30 |
| NCT05003310Arthritis, Rheumatoid · United States, Netherlands | – | Recruiting | Galvani Bioelectronics | Jul 2027 | 28 |
| NCT04517253Nakajo syndrome · Japan | 3 | Terminated | Eli Lilly | Apr 4, 2023 | 10 |
| NCT04421027COVID-19 · United States, Argentina, Brazil and more | 3 | Completed | Eli Lilly | Feb 12, 2021 | 1,525 |
| NCT04088409Uveitis · France, Germany, Italy and more | 3 | Active, not recruiting | Eli Lilly | Jul 17, 2023 | 30 |
| NCT04088396Arthritis, Juvenile · Argentina, Belgium, Brazil and more | 3 | Active, not recruiting | Eli Lilly | Oct 2026 | 58 |
| NCT04086745Arthritis, Rheumatoid · United States | 4 | Completed | Eli Lilly | May 19, 2025 | 1,050 |
| NCT03952559Dermatitis, Atopic · Argentina, Australia, Austria and more | 3 | Completed | Eli Lilly | Apr 24, 2022 | 516 |
| NCT03915964Arthritis, Rheumatoid · United States, Australia, Austria and more | 4 | Completed | Eli Lilly | May 28, 2025 | 2,659 |
| NCT03899259Alopecia Areata · United States, Argentina, Australia and more | 3 | Completed | Eli Lilly | Jan 24, 2021 | 606 |
| NCT03843125Lupus Erythematosus, Systemic · United States, Argentina, Australia and more | 3 | Terminated | Eli Lilly | Apr 1, 2022 | 1,147 |
| NCT03773978Arthritis, Juvenile · Argentina, Australia, Austria and more | 3 | Completed | Eli Lilly | Jan 26, 2022 | 220 |
| NCT03773965Arthritis, Juvenile · Argentina, Australia, Austria and more | 3 | Recruiting | Eli Lilly | Jul 2031 | 190 |
| NCT03742973Liver Cirrhosis, Biliary · United States, Puerto Rico | 2 | Terminated | Eli Lilly | Sep 26, 2019 | 2 |
| NCT03733301Dermatitis, Atopic · Argentina, Australia, Austria and more | 3 | Completed | Eli Lilly | Jul 29, 2019 | 329 |
| NCT03616964Lupus Erythematosus, Systemic · United States, Argentina, Chile and more | 3 | Completed | Eli Lilly | Sep 24, 2021 | 778 |
| NCT03616912Lupus Erythematosus, Systemic · United States, Australia, Austria and more | 3 | Terminated | Eli Lilly | Nov 1, 2021 | 830 |
| NCT03570749Alopecia Areata · United States, Japan, Mexico and more | 3 | Completed | Eli Lilly | Feb 2, 2021 | 784 |
| NCT03559270Dermatitis, Atopic · United States, Canada, Puerto Rico | 3 | Terminated | Eli Lilly | Oct 14, 2021 | 374 |
| NCT03435081Dermatitis, Atopic · United States, Canada, Puerto Rico | 3 | Completed | Eli Lilly | Dec 9, 2019 | 440 |
| NCT03428100Dermatitis, Atopic · Austria, Belgium, Brazil and more | 3 | Completed | Eli Lilly | Nov 25, 2019 | 463 |
| NCT03334435Dermatitis, Atopic · Argentina, Australia, Austria and more | 3 | Completed | Eli Lilly | Sep 21, 2020 | 1,645 |
| NCT03334422Dermatitis, Atopic · Argentina, Australia, Austria and more | 3 | Completed | Eli Lilly | Dec 12, 2018 | 615 |
| NCT03334396Dermatitis, Atopic · Czechia, Denmark, France and more | 3 | Completed | Eli Lilly | Dec 6, 2018 | 660 |
| NCT03212638Healthy · Singapore | 1 | Completed | Eli Lilly | Jul 31, 2017 | 42 |
| NCT02758613Healthy · China | 1 | Completed | Eli Lilly | Jul 2016 | 33 |
| NCT02708095Lupus Erythematosus, Systemic · United States, Argentina, Austria and more | 2 | Completed | Eli Lilly | Oct 12, 2017 | 314 |
| NCT02576938Dermatitis, Atopic · United States, Japan | 2 | Completed | Eli Lilly | Feb 2017 | 124 |
| NCT02340104Healthy Volunteers · United Kingdom | 1 | Completed | Eli Lilly | Feb 2015 | 8 |
| NCT02265705Arthritis, Rheumatoid · Argentina, Brazil, China | 3 | Completed | Eli Lilly | May 2017 | 290 |
| NCT02263911Healthy Participants · Japan | 1 | Completed | Eli Lilly | Dec 2014 | 16 |
| NCT01968057Healthy Volunteers · United Kingdom | 1 | Completed | Eli Lilly | Dec 2013 | 18 |
| NCT01937026Healthy Volunteers · United Kingdom | 1 | Completed | Eli Lilly | Nov 2013 | 18 |
| NCT01925144Healthy Volunteers · United Kingdom | 1 | Completed | Eli Lilly | Nov 2013 | 30 |
| NCT01924299Healthy Volunteers · United Kingdom | 1 | Completed | Eli Lilly | Nov 2013 | 36 |
| NCT01910311Healthy Volunteers · United Kingdom | 1 | Completed | Eli Lilly | Oct 2013 | 18 |
| NCT01896726Healthy Volunteers · United Kingdom | 1 | Completed | Eli Lilly | Oct 2013 | 20 |
| NCT01885078Arthritis, Rheumatoid · United States, Argentina, Australia and more | 3 | Completed | Eli Lilly | Nov 12, 2020 | 2,877 |
| NCT01870388Liver Diseases · United States | 1 | Completed | Eli Lilly | Jul 2013 | 16 |
| NCT01859078Healthy Volunteers · United Kingdom | 1 | Completed | Eli Lilly | Aug 2013 | 28 |
| NCT01721057Arthritis, Rheumatoid · United States, Argentina, Australia and more | 3 | Completed | Eli Lilly | Sep 2014 | 684 |
| NCT01721044Arthritis, Rheumatoid · United States, Argentina, Australia and more | 3 | Completed | Eli Lilly | Jun 2014 | 527 |
| NCT01711359Arthritis, Rheumatoid · United States, Argentina, Austria and more | 3 | Completed | Eli Lilly | Feb 2015 | 588 |
| NCT01710358Arthritis, Rheumatoid · United States, Argentina, Belgium and more | 3 | Completed | Eli Lilly | Mar 2015 | 1,307 |
| NCT01683409Diabetic Nephropathies · United States, Japan, Mexico and more | 2 | Completed | Eli Lilly | Sep 2014 | 130 |
| NCT01536951Healthy Participants · United States | 1 | Completed | Eli Lilly | May 2013 | 62 |
| NCT01490632Psoriasis · United States, Canada, Japan and more | 2 | Completed | Eli Lilly | Dec 2012 | 271 |
| NCT01469013Arthritis, Rheumatoid · Japan | 2 | Completed | Eli Lilly | Nov 2012 | 145 |
| NCT01398475Arthritis, Rheumatoid · Singapore | 1 | Completed | Eli Lilly | Sep 2011 | 15 |
| NCT01299285Healthy Volunteers · United States | 1 | Completed | Eli Lilly | Mar 2011 | 6 |
| NCT01247350Healthy Volunteer · United States | 1 | Completed | Eli Lilly | Apr 2011 | 34 |
| NCT01185353Arthritis, Rheumatoid · United States, Croatia, Czechia and more | 2 | Completed | Eli Lilly | Dec 2011 | 301 |
| NCT00902486Arthritis, Rheumatoid · United States, Czechia | 2 | Completed | Incyte | Jun 2010 | 127 |
How it is read
Names in the registry
- “Baricitinib”, 53 entries
- “LY3009104”, 5 entries
- “INCB028050”, 3 entries
- “Barcimiant”, 1 entry
- “Baricitinib suspension”, 1 entry
Conditions, from the studies’ own filings
- Arthritis, Rheumatoid, 13 studies
- Dermatitis, Atopic, 9 studies
- Lupus Erythematosus, Systemic, 4 studies
- COVID-19, 3 studies
- Arthritis, Juvenile, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.